Reiner, Ž. (2018). PCSK9 inhibitors in clinical practice: Expectations
and reality. Atherosclerosis (Amsterdam), 270., 187-188. doi: 10.1016/j.atherosclerosis.2018.01.001
Reiner, Željko. "PCSK9 inhibitors in clinical practice: Expectations
and reality." Atherosclerosis (Amsterdam), vol. 270, 2018, pp. 187-188. https://doi.org/10.1016/j.atherosclerosis.2018.01.001
Reiner, Željko. "PCSK9 inhibitors in clinical practice: Expectations
and reality." Atherosclerosis (Amsterdam) 270 (2018): 187-188. https://doi.org/10.1016/j.atherosclerosis.2018.01.001
Reiner, Ž. (2018) 'PCSK9 inhibitors in clinical practice: Expectations
and reality', Atherosclerosis (Amsterdam), 270, pp. 187-188. doi: 10.1016/j.atherosclerosis.2018.01.001
Reiner Ž. PCSK9 inhibitors in clinical practice: Expectations
and reality. Atherosclerosis (Amsterdam) [Internet]. 2018 [cited 2024 August 20];270:187-188. doi: 10.1016/j.atherosclerosis.2018.01.001
Ž. Reiner, "PCSK9 inhibitors in clinical practice: Expectations
and reality", Atherosclerosis (Amsterdam), vol. 270, pp. 187-188, 2018. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:184:226642. [Accessed: 20 August 2024]